1.80EUR
343.00 MEUR
5.25 BEUR
117.23 M
About UCB S.A.
Sector
CEO
Jean-Christophe Tellier
Headquarters
Brussels
Website
Employees (FY)
9.08 K
Founded
1925
ISIN
BE0003739530
FIGI
BBG000BMYT43
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
UCB.BR short term bullish potential to challenge ATHConclusion:
A substantial break above 100, preferably above 107 signals a short term bullish potential, challenging ATH and beyond.
A drop below 75 on the other hand renders long term bearish or at least choppy consolidation.
For short term play targeting 108 minimally, with tight stop just under 96
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange UCB S.A. stocks are traded under the ticker UNC.
UCB S.A. is going to release the next earnings report on Jul 25, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for UCB S.A. has a max estimate of 165.00 EUR and a min estimate of 105.00 EUR.
UNC earnings for the last quarter are 2.63 EUR whereas the estimation was 1.69 EUR which accounts for 55.93% surprise. Estimated earnings for the next quarter are 1.34 EUR. See more details about UCB S.A. earnings.
UCB S.A. revenue for the last quarter amounts to 2.59 B EUR despite the estimated figure of 2.54 B EUR. In the next quarter revenue is expected to reach 2.54 B EUR.
Yes, you can track UCB S.A. financials in yearly and quarterly reports right on TradingView.
UNC net income for the last quarter is 32.00 M EUR, while the quarter before that showed 311.00 M EUR of net income which accounts for −89.71% change. Track more UCB S.A. financial stats to get the full picture.
Yes, UNC dividends are paid annually. The last dividend per share was 0.93 EUR. As of today, Dividend Yield (TTM)% is 0.78%. Tracking UCB S.A. dividends might help you take more informed decisions.
UCB S.A. dividend yield was 1.21% in 2023, and payout ratio reached 52.65%. The year before the numbers were 1.27% and 42.23% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, UNC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade UCB S.A. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 9.08 K employees. See our rating of the largest employees — is UCB S.A. on this list?
We've gathered analysts' opinions on UCB S.A. future price: according to them, UNC price has a max estimate of 165.00 EUR and a min estimate of 105.00 EUR. Read a more detailed UCB S.A. forecast: see what analysts think of UCB S.A. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. UCB S.A. EBITDA is 1.35 B EUR, and current EBITDA margin is 18.47%. See more stats in UCB S.A. financial statements.